Chlorpheniramine/Hyoscyamine
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Every FDA drug recall initiated in 2022, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.
1,390 recalls, newest first.
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Presence of Particulate Matter: Glass particulate matter detected in injectable.
CGMP Deviations: Raw material recalled by repackager, due to discoloration.
Failed impurities/degradation specifications: Out of specification for unknown impurities.
Failed Stability Specifications: Out of specification for weight loss at the 18-month stability timepoint and projected weight loss of 21.1% at shelf life.
Failed Impurities/Degradations Specifications
Failed Impurities/Degradation specifications
Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product
Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product
Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.
Failed Impurities/Degradation Specifications
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.
cGMP Deviations
cGMP Deviations
cGMP Deviations
cGMP Deviations
CGMP Deviations: Impurities of acetal and acetaldehyde were discovered in the product in excess of allowed limits.